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Over the past several years, problems related
to conflicts of interest in peer review have
received considerable attention in the scien-
tiﬁc literature and national press (Harris and
Berenson 2005; Steinbrook 2005; Waldman
2005). In response, several scientiﬁc journals
and international agencies overseeing expert
scientiﬁc review panels have added stringent
rules to reveal real or apparent ﬁnancial con-
ﬂicts of interest by individuals or commercial
entities (Cogliano et al. 2004). The deter-
mination of a real or apparent conflict of
interest may result in limitation or disqualiﬁ-
cation of individuals from participation on
expert panels.
In contrast to these circumstances, con-
ﬂicts of interest are an inherent component of
science-based litigation and generally include
presentations and interpretations of studies
that are fashioned to appear consistent and
favorable with the position of the sponsor.
This situation puts an enormous burden on
judges and juries, forcing them to wade
through disguised biases in order to decipher
assertions from facts. Because of uncertainties
in extrapolations of toxicologic ﬁndings from
studies in experimental animals to human risk
and uncertainties in the costs associated with
reduction or elimination of human exposures
to those agents, numerous conflicts have
arisen and continue to arise over the reliability
of identified health effects of specific sub-
stances. In one view, precautionary health
measures to prevent disease are advocated in
spite of uncertainties of the magnitude of
potential human risks, whereas the alternative
perspective argues that additional costs for
exposure reduction are not warranted until
adverse health effects are clearly demonstrated
in humans. Conﬂicting views on the relative
importance of toxicologic research seem to
originate largely from concerns of predictabil-
ity and impacts on human health risks versus
impacts on costs and proﬁts.
Although science seeks to expand our
knowledge of facts and truths through the
principles of hypothesis generation and
hypothesis testing, the way in which our
knowledge grows and reflects the truth
depends on how questions are framed, how
rigorously hypotheses are tested, and to what
extent assertions extend beyond actual find-
ings and are portrayed as established facts.
Consequently, there are several ways in which
conflicting views may arise in health effects
research. Failure to adequately test hypotheses
or speculations with appropriately challeng-
ing experiments does not advance science
and, more important, can produce erroneous
opinions of potential health effects of particu-
lar agents. Reliance on untested hypotheses
that are promoted to explain away adverse
outcomes may have serious public health
consequences if future testing of alleged mech-
anisms shows them to be incorrect (Tomatis
2002). This article focuses on principles of
design and evaluation of animal carcinogenic-
ity studies, their utility for determining disease
causality, and potential sources of conﬂicting
views on chemical carcinogenesis.
Use of Animal Studies for
Public Health Decisions
There are several advantages and disadvantages
in assessing human cancer risk from animal
studies. Animal models are used in preclinical
trials of new pharmaceutical agents before test-
ing in humans because of species similarities in
the biology of disease processes. The same pre-
dictive value of experimental animal studies
has been applied to assessments of potential
toxic and carcinogenic agents in our environ-
ment. A major advantage of animal studies is
the elimination of the need to wait for a high
incidence of human cancers (which may clini-
cally manifest as much as 30 years from time
of ﬁrst exposure) before implementing public
health–protective strategies. Because exposure
conditions can be ﬁnely controlled in animal
studies, they are easier to interpret and assign
causality. In contrast, retrospective epidemiol-
ogy studies typically have limited exposure
information, especially at times early in tumor
development, and confounding factors are not
always known.
Animal carcinogenicity studies can be
performed in less time and at lower costs than
epidemiology studies. The major disadvan-
tages of animal studies are that they require
extrapolations across species and dose.
Furthermore, animal studies do not capture
the full range of human variability due to dif-
ferences in genetics, health status, diet,
lifestyle, and other exposures.
Because all known human carcinogens
that have been studied adequately in experi-
mental animals produced positive carcinogenic
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Conflicting views have been expressed frequently on assessments of human cancer risk of
environmental agents based on animal carcinogenicity data; this is primarily because of uncertainties
associated with extrapolations of toxicologic ﬁndings from studies in experimental animals to human
circumstances. Underlying these uncertainties are issues related to how experiments are designed, how
rigorously hypotheses are tested, and to what extent assertions extend beyond actual findings.
National and international health agencies regard carcinogenicity ﬁndings in well-conducted experi-
mental animal studies as evidence of potential carcinogenic risk to humans. Controversies arise when
both positive and negative carcinogenicity data exist for a speciﬁc agent or when incomplete mecha-
nistic data suggest a possible species difference in response. Issues of experimental design and evalua-
tion that might contribute to disparate results are addressed in this article. To serve as reliable sources
of data for the evaluation of the carcinogenic potential of environmental agents, experimental studies
must include a) animal models that are sensitive to the end points under investigation; b) detailed
characterization of the agent and the administered doses; c) challenging doses and durations of expo-
sure (at least 2 years for rats and mice); d) sufﬁcient numbers of animals per dose group to be capable
of detecting a true effect; e) multiple dose groups to allow characterization of dose–response relation-
ships, f) complete and peer-reviewed histopathologic evaluations; and g) pairwise comparisons and
analyses of trends based on survival-adjusted tumor incidence. Pharmacokinetic models and mecha-
nistic hypotheses may provide insights into the biological behavior of the agent; however, they must
be adequately tested before being used to evaluate human cancer risk. Key words: dose selection, maxi-
mally tolerated dose, mode of action, rodent cancer bioassay, statistical power, tumor pathology.
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[Online 7 November 2007]results, public health agencies, including the
International Agency for Research on Cancer
(IARC 2000), the National Toxicology
Program (NTP 2004), and the U.S.
Environmental Protection Agency (U.S. EPA
2005), have endorsed the perspective that
in the absence of adequate data in humans, it is
biologically plausible and prudent to regard agents
and mixtures for which there is sufﬁcient evidence
of carcinogenicity in experimental animals as if
they presented a carcinogenic risk to humans.
(IARC 2000)
No alternative experimental approach has been
shown to be as reliable for assessing human
cancer risk (Tomatis et al. 2001). Hence, even
in the absence of adequate human data, public
health agencies have classiﬁed agents as possi-
bly/probably (IARC 2000), likely (U.S. EPA
2005), or reasonably anticipated (NTP 2004)
to be a human carcinogen if there is sufﬁcient
evidence in animals. Sufficient evidence
includes a) an increased incidence of malignant
or malignant and benign tumors combined in
two or more species or at multiple sites, b)a n
increased incidence in two or more indepen-
dent studies in one species, or c) an increased
incidence in a single study in one species if
malignant tumors occur to an unusual degree
in incidence, site, type, or age of onset. As
noted below, mechanistic data on relevant bio-
logical activities of the substance can also inﬂu-
ence the overall cancer risk classiﬁcation.
Experimental Design Issues
The outcome of an animal carcinogenicity
study may be affected by several experimental
design factors. Differences in experimental
design can lead to inconsistent results and
conflicting views on the potential health
effects of the agent under study. For example,
early studies on benzene failed to detect car-
cinogenic effects in animals, even though epi-
demiology studies had demonstrated a causal
association between benzene exposure and
leukemia in humans. Deﬁciencies in the early
animal studies included too few animals, lack
of controls, short study duration, and inade-
quate levels of exposure. Subsequent, better-
designed studies by Maltoni et al. (1989) and
by Huff et al. (1989) established benzene as a
potent, multisite carcinogen in rats and mice.
Some experimental design issues that can lead
to conflicting results and interpretations on
the carcinogenicity activity of a chemical are
discussed below.
Chemical. To best understand the toxico-
logic properties of a particular agent, the
chemical should be tested at high purity. This
ensures that the agent under study is responsi-
ble for any observed effects and that contami-
nants are not the cause or modifier of that
response. When a potentially active contami-
nant is present, claims are frequently made
that the contaminant and not the principal
agent is responsible for any observed carcino-
genic response. For example, when the
hepatocarcinogenicity of industrial-grade
trichloroethylene (TCE) in mice was reported
by the National Cancer Institute (1976),
Henschler et al. (1977) suggested that the sta-
bilizer epichlorohydrin and not TCE was the
causal agent. However, a subsequent study of
TCE without epichlorohydrin produced a
similar response, conﬁrming the carcinogenic-
ity of TCE (NTP 1990). Resolving all ques-
tions about the observed adverse health effects
of environmental pollutants such as TCE is
time consuming and costly. Health agencies
should not allow these types of assertions to
cause delays in actions necessary to reduce
human exposures.
Before exposing animals to the agent, it is
necessary to ascertain the stability and expo-
sure uniformity of the chemical under condi-
tions that simulate the conditions of the study
(NTP 2006a). If the agent degrades or evapo-
rates during exposure, the accuracy of the tar-
geted administered dose is compromised and
degradation products may contribute to any
observed response.
Animal models. Rats and mice are the two
species most typically used in cancer bioassays
because they have life spans of about 2.5 years
and studies of up to 1,000 animals can be
performed in reasonably sized animal rooms.
Strains of animals used should be ones that
have adequate longevity, genetic stability, and
few spontaneous diseases that might shorten
their life span, mask any chemical-induced
effects, or impair metabolism/elimination of
the test agent (Rao et al. 1988). It is difﬁcult
to detect responses in organs with very high
background tumor rates (e.g., interstitial cell
tumors of the testis in F344 rats). Both sexes
of two species should be used to identify any
sex-specific responses and confirm multiple
species effects.
A major shortcoming of the rodent cancer
bioassay is its limited statistical power to esti-
mate the true response rate (Haseman 1983).
Power is the probability of detecting an effect
(rejecting the null hypothesis) when an effect
exists; it is inﬂuenced by the sample size, the
background rate, and the magnitude of the
true response (Haseman 1984). The power
limitation of the bioassay may lead to conﬂicting
views of study results when nonsigniﬁcant ele-
vations in incidence are detected in treatment
groups of small size. Small sample size was the
basis of conﬂicting views expressed on the sig-
niﬁcance of tumors found in long-term toxic-
ity studies of dichlorodiphenyltrichloroethane
(DDT) in monkeys (Takayama et al. 1999;
Tomatis and Huff 2000).
Exposure. Because of the limited statistical
power of the bioassay when group size is only
about 50 animals per sex per dose, high doses
are necessary to identify potential carcinogenic
hazards, whereas multiple dose groups are
used to characterize dose–response relation-
ships. The selection of dose levels is a critical
aspect of the experimental design and is a
major source of conﬂicting views in the inter-
pretation of study results. Data from
prechronic or subchronic studies (4–13 weeks’
duration) are used to estimate the maximally
tolerated dose or the minimally toxic dose
(MTD).
Lower doses (1/2 MTD and 1/4 to 1/10
MTD) are used in case the highest dose
selected for the chronic study is found to be
too high (excessive mortality) and to provide
information on dose–response relationships
(Bucher et al. 1996). Pharmacokinetic infor-
mation should also be used to ensure that no
more than one of the selected doses is above a
level that saturates the processes of absorp-
tion, metabolic activation, or detoxification.
A cancer bioassay that uses only saturating
doses would not be very informative in char-
acterizing dose–response relationships at
lower exposures. For example, carcinogenicity
studies of 1,3-butadiene in rats were con-
ducted with exposure concentrations of 1,000
and 8,000 ppm (Owen et al. 1987), although
metabolism of this gas in rats is linear up to
about 1,000 ppm (Bolt et al. 1984). A better
characterization of the true dose–response can
be achieved with larger numbers of properly
spaced dose groups (Figure 1A) (e.g., five-
dose study of 1,3-butadiene in mice at
6.25–625 ppm; Melnick et al. 1990) versus
only two widely spaced dose groups
(Figure 1B). Unless group size is extremely
large (i.e., several hundred to thousands of
animals per group), the selection of only low
doses for the cancer bioassay or short exposure
durations can lead to a misinterpretation of
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Figure 1. Tumor dose–response curves: (A) ﬁve dose groups plus control; (B) a high-dose group, a much
lower dose group, and control; (C) two low-dose groups plus control.
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) A B Cthe carcinogenic potential of the agent under
study and its potential risk at human exposure
levels (Figure 1C). For example, chronic
studies of p-dichlorobenzene failed to detect a
carcinogenic effect in rats or mice exposed up
to 500 ppm by inhalation for 76 or 57 weeks,
respectively (Loeser and Litchfield 1983); in
contrast, signiﬁcant increases in kidney tumors
in male rats and liver tumors in male and
female mice were observed in 2-year gavage
studies of p-dichlorobenzene at doses up to
300 or 600 mg/kg, respectively (NTP 1987).
Typical carcinogenicity studies in rats and
mice involve exposures beginning at 6 weeks
of age and continuing for 2 years; this expo-
sure period corresponds roughly with early
adulthood through most of an occupational
life span. Earlier periods of exposure should
be included if there is reason to believe that
susceptibility may be greater during growth
and early developmental stages, for example,
mutagens (Rice et al. 1989) and endocrine
disruptors such as diethylstilbestrol (Herbst
et al. 1979). The 2-year duration limit was
selected to minimize late-developing back-
ground tumor responses in controls and in
exposed animals that might preclude the abil-
ity to detect significant chemical-induced
effects. Exposure durations shorter than
2 years are also problematic because of their
reduced sensitivity to detect increases in late-
appearing tumors that are related to treatment
with the test agent (Haseman et al. 2001).
Evaluation Issues
The conduct and evaluation of a cancer bioas-
say require a multidisciplinary effort, includ-
ing expertise from toxicologists, laboratory
animal veterinarians, chemists, histologists,
pathologists, cellular/molecular biologists, and
statisticians. Topics that affect the interpreta-
tion of a properly conducted carcinogenicity
study include the thoroughness of the
histopathologic evaluations, the statistical
analyses, and the appropriate application of
mode-of-action hypotheses.
Histopathology. The detection of nonneo-
plastic and neoplastic lesions in animals
depends on the thoroughness of the necrop-
sies and the microscopic examinations per-
formed. A proper evaluation necessitates that
all organs and tissues be examined and that
moribund animals be removed from the study
and sacriﬁced immediately to avoid autolytic
destruction of cells and tissues (NTP 2006a).
Tissue autolysis can interfere with the detec-
tion and diagnosis of chemical-induced
lesions and, consequently, reduce the power
of the study. In some cases, multiple section-
ing of an organ in exposed and control groups
may be necessary to obtain a more accurate
estimate of the incidence of neoplastic lesions,
especially for small lesions that may not be
detected at necropsy (Eustis et al. 1994). The
incidence of renal tubule adenomas was
found to be increased significantly in male
rats exposed to benzophenone after additional
sections of kidneys from control and treated
rats were examined microscopically (NTP
2006b). Without the examination of addi-
tional sections, this effect might have been
missed. Although diagnostic criteria have
been established for most observable lesions,
it is not unusual for pathologists to disagree in
their judgment of lesions, especially those that
are part of a continuum of progressive
change. Studies that lack independent pathol-
ogy peer review (Boorman et al. 1985) may
yield diagnostic data that would not be gener-
ally accepted by rodent pathologists. The use
of multiple terms for similar lesions or not
properly combining related tumors could lead
to underdiagnosis of a chemical-related effect.
For example, when the incidences of neu-
roglial tumors in rats exposed to 1,3-butadi-
ene (Owen et al. 1987) were combined, an
additional carcinogenic effect of this chemical
became apparent (Melnick and Huff 1992).
In addition to statistical analyses described
below, other factors may contribute to the
interpretation of tumor data, including a) the
occurrence of common versus uncommon
tumors; b) evidence of progression of lesions,
such as benign to malignant where it is appro-
priate to combine (McConnell et al. 1986), or
preneoplastic to neoplastic; c) tumor occur-
rence with reduced latency; d) multiplicity in a
site-specific tumor response; e) evidence of
metastases; and f) supporting evidence of pro-
liferative preneoplastic lesions at the same site
or detection of the same lesion in the other sex
or species. Ignoring this type of information
could lead to faulty interpretations of chemi-
cal-induced carcinogenic effects. For example,
a nonstatistically signiﬁcant increase in urinary
bladder tumors in female rats (2 of 49, 4%) is
considered to be related to anthraquinone
exposure because of the low historical rate of
this neoplasm (0.1%) and the marginally
increased incidences of hyperplasia of the
bladder transitional epithelium (NTP 2005a).
Similarly, nonstatistically signiﬁcant increases
in thyroid follicular cell tumors in rats are con-
sidered to be related to sodium chlorate expo-
sure because the incidences exceeded historical
control rates, and incidences of follicular cell
hypertrophy were increased in all exposure
groups (NTP 2005b).
Statistics. If mortality in a dose group is
different from that of controls, it is critical
that pairwise comparisons and analyses of
trends be based on survival-adjusted tumor
rates (Haseman 1984). The reason for this
adjustment is that if animals died early from
causes other than tumors at the organ site of
interest, then those animals would not have
been on study long enough to provide a full
contribution of risk to that study group.
Failure to adjust for differences in survival
(e.g., Owen et al. 1987) could yield unreliable
estimates of cancer risk and possible misinter-
pretations of a true site-speciﬁc effect.
Although comparisons between the con-
current control group and the exposure groups
are the most valid for identifying chemical-
induced effects, comparisons with historical
control data may also be helpful in interpreting
treatment-related effects (Haseman et al.
1984). For meaningful comparisons, the con-
ditions of the current study must be similar to
those in the historical database and diagnostic
criteria must be identical. Thus, comparisons
must be speciﬁc for the species, sex, and strain
of animals and for the route of exposure and
the diet. Conﬂicting interpretations of study
ﬁndings may arise with improper use of histor-
ical databases. For one, the specifications of
equivalent study conditions and diagnostic cri-
teria noted above must be followed. For exam-
ple, although Bird et al. (1997) observed a
signiﬁcant dose-related increase in incidences
of testicular tumors in F344 rats exposed to
methyl-t-butyl ether by inhalation for 2 years
(64% controls, 70% at 400 ppm, 82% at
3,000 ppm, and 94% at 8,000 ppm), these
ﬁndings were dismissed by the authors, as well
as by an IARC review panel (IARC 1999a).
This decision was based on the perception that
the high rate of interstitial cell tumors in
untreated male F344 rats makes statistical
increases in these rates meaningless, and on
claims that the increases in exposed groups
were due to a low incidence in the control
group compared with historical controls.
However, the incidence of testicular tumors in
the control group was essentially the same as
the historical control rate of testicular tumors
in F344 rats in inhalation studies (Nyska et al.
1998). In addition, similar increases in testicu-
lar interstitial cell tumors in inhalation studies
of ethylbenzene (NTP 1999a) and isoprene
(NTP 1999b) in F344 rats were considered
related to chemical exposures. In some cases,
excessive reliance has been placed on the range
of historical response rather than the mean
tumor incidence and its measure of variability.
This can be problematic if an extreme value in
the database contains an outlier value that is
not relevant to the current study being evalu-
ated. In such a case, it would be inappropriate
to ignore an increased tumor incidence that
falls within the historical control range but is
much greater (e.g., > 2 SD) than the historical
mean control tumor incidence.
Mechanistic considerations: dosimetry. A
critical step in assessing human cancer risk
from data obtained in animal studies is to
estimate an appropriate human equivalent
dose metric. The extrapolation of dose across
species is typically performed by scaling in
relation to body weight or through the use of
physiologically based pharmacokinetic
Melnick et al.
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quantitative terms the complex physiologic
and biochemical processes that affect the
absorption, distribution, metabolism, and
elimination of the agent of concern. These
models are developed to describe relationships
between exposure to toxic agents, the internal-
ized dose, and the time-dependent tissue
concentrations of parent compound and bio-
logically active metabolites. Conﬂicting views
in estimations of human dose may arise
because of various assumptions used to deter-
mine chronic dose levels by scaling or PBPK
modeling. For example, the assumption made
in many models that a unique set of metabolic
parameters, which in some cases are derived
from short exposures of young healthy indi-
viduals, can be scaled as a function of body
weight to provide precise estimates of the
behavior of the agent in genetically diverse
populations (e.g., TCE: Clewell et al. 2000;
Fisher 2000) is unrealistic.
Additional uncertainties in model parame-
ters arise because multiple isozymes may be
involved in the activation or detoxification
pathways, and in addition to large differences
in enzyme activities due to genetic diversity,
individuals may be exposed differently to
other agents that can affect the levels of acti-
vating or detoxifying enzymes. Simply ﬁtting a
model to limited data sets does not provide
any assurance that model-based assumptions
are reliable. All model assumptions must be
made explicit and evaluated for their impact
on model predictions. Conﬁrmation of model
predictions by subsequent experimentation is
essential for hypothesis testing and model
validation (Kohn 1995).
Mechanistic considerations: mode of
action. Results from animal or in vitro studies
that attempt to determine the mode of action
for disease induction have been used by pub-
lic health agencies to upgrade or downgrade
cancer risk classifications of agents that have
inadequate or limited evidence in humans.
Consider the family of vinyl halides, which
includes vinyl chloride (VCl; a known human
carcinogen), vinyl bromide (VBr), and vinyl
ﬂuoride (VF). These three chemicals are acti-
vated by enzymes found in humans (cyto-
chrome P450–dependent monooxygenases,
primarily CYP2E1) to epoxides that can react
with DNA (Guengerich et al. 1991) to form
promutagenic DNA adducts. In animals or
in vitro systems, the same DNA adducts are
formed with VCl, VBr, or VF. Experimental
carcinogenicity studies have shown that these
three chemicals induce neoplasms of the circu-
latory system (angiosarcomas), as well as other
types of tumors, in rats and mice (Melnick
2002). To consider VBr or VF as anything less
than a human carcinogen is unethical. Because
VCl is known to cause angiosarcomas in
humans, VBr and VF should be classified as
human carcinogens without requiring conﬁrm-
ing evidence from studies in humans.
Based on mechanistic data, IARC and
NTP upgraded ethylene oxide (IARC 1994;
NTP 2004) and 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) (IARC 1997; NTP 2004)
from “probable” or “reasonably anticipated”
human carcinogens to “known human carcino-
gens.” In both cases, the evidence of carcino-
genicity was limited in humans and sufﬁcient
in experimental animals. The upgrading of eth-
ylene oxide was based largely on results in
exposed workers that showed induction of
chromosomal aberrations in peripheral lym-
phocytes, the presence of micronuclei in bone
marrow cells, and hemoglobin adducts in
blood samples. The upgrading of TCDD was
based on data demonstrating that the multi-
site carcinogenicity of this chemical in experi-
mental animals was due to a mechanism
involving activation of the aryl hydrocarbon
receptor and studies showing that this recep-
tor is highly conserved across species and
functions the same way in humans and in
experimental animals.
On the other hand, IARC downgraded
the classiﬁcation of di(2-ethylhexyl)phthalate
(DEHP) from “possibly” to “not classifiable
as to its carcinogenicity to humans” (IARC
2000). This was done despite the fact that the
evidence of carcinogenicity of DEHP, based
on increased incidences of liver tumors in rats
and mice, was concluded to be sufficient in
animals. Strangely, data on pancreatic tumors
induced by DEHP in rats were also available
(David et al. 2000) but not reviewed by the
IARC working group. The downgrading of
the animal cancer evidence was based on the
panel’s acceptance of the hypothesis that
DEHP induces liver tumors in rats and mice
by a non-DNA-reactive mechanism involving
peroxisome proliferation. This mechanism
was considered not to be relevant to humans
because peroxisome proliferation had not
been documented either in human hepatocyte
cultures exposed to DEHP or in the liver of
exposed nonhuman primates. The IARC
decision seems unreasonable because peroxi-
some proliferation alone does not provide a
mechanistic explanation for the different car-
cinogenic potencies of peroxisome prolifera-
tors in the rat liver (Marsman et al. 1988).
Peroxisomes are subcellular structures that
contain several oxidase enzymes. Agents that
cause increases in their numbers are called per-
oxisome proliferators. Many peroxisome prolif-
erators are rodent carcinogens, and the mode
of action proposed for rodent liver tumor
induction by peroxisome proliferators involves
activation of the peroxisome proliferator–
activated receptor (PPARα), which results in
altered transcription rates of genes that regulate
cell proliferation and apoptosis (programmed
cell death) (Klaunig et al. 2003). However, this
hypothesis has not been tested with experimen-
tal studies demonstrating consistent increases
in liver tumor incidence as a direct function of
the time-dependent induction of cell prolifera-
tion and suppression of apoptosis in rats and
mice treated with peroxisome proliferators. An
apparent problem with this hypothesis is that
increases in cell proliferation are generally only
a transient response that returns to control
levels within about 2–4 weeks after initiation
of continuous exposure, whereas tumor
induction requires chronic exposure for most
peroxisome proliferators.
Peroxisome proliferation per se does not
appear to be a causal event in liver carcinogene-
sis (Melnick 2001) and therefore may not be a
reliable marker for evaluating human cancer
risk. Humans express a functionally active
PPARα (Sher et al. 1993), and hypolipidemic
ﬁbrates modulate lipid homeostasis in humans
through activation of this receptor (Schoonjans
et al. 1996). Species differences in peroxisome
proliferation have been suggested to be due to
lower levels of PPARα mRNA in the liver
of humans compared with rats and mice
(Tugwood et al. 1996). Although stimulation
of cell proliferation and suppression of apopto-
sis have been suggested to favor the prolifera-
tion and persistence of DNA-damaged cells
that eventually progress to tumors, altered
expression of cell growth and apoptosis genes
by DEHP has not been demonstrated to be
dependent on PPARα activation (Klaunig
et al. 2003). In fact, growth factors produced
in Kupffer cells by a PPARα-independent
pathway are essential for the induced cell pro-
liferation and suppression of apoptosis by per-
oxisome proliferators (Peters et al. 2000). It is
clear that the mechanism of tumor induction
by DEHP is not known, and a greater under-
standing of the interplay between PPARα acti-
vation and PPARα-independent Kupffer cell
activation is needed. Thus, available mechanis-
tic data do not support IARC’s decision to
downgrade DEHP (IARC 2000) based on the
hypothesis that liver tumor induction in rats
and mice occurs by a mechanism involving
peroxisome proliferation that is not relevant to
humans. In a recent study, Ito et al. (200)
showed that dietary administration of DEHP
induces liver tumors in mice lacking a func-
tional PPARα gene. This ﬁnding emphasizes
the need to test mechanistic hypotheses that, if
relied on, might lead to erroneous cancer risk
classifications and inadequately protective
public health decisions.
Conclusions
Appropriately conducted animal cancer stud-
ies remain the most reliable means of identify-
ing agents that pose a potential human cancer
risk. However, as noted above, there are
numerous ways in which experimental
designs and interpretations can be or have
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been manipulated or misinterpreted to pro-
duce false-negative responses. Studies that use
too low doses, too few animals, or too short a
duration, as well as evaluations that are based
on incomplete necropsy or histopathology, do
not combine related tumor effects, fail to
adjust for differences in animal survival, or
incorrectly use historical control data, would
not be expected to produce reliable informa-
tion on chemical carcinogenesis. It is also
important to recognize that rats and mice
may be insensitive to certain types of cancers
(e.g., prostate) and that timing of exposure
may be critical in initiating a carcinogenic
response. Thus, the lack of an increased
tumor incidence in an adequately conducted
2-year animal study does not necessarily sig-
nify that the chemical lacks carcinogenic
activity in people.
The observation of consistent dose–
response relationships between early cellular
and molecular responses and tumor induction
in laboratory animals may serve as the basis
for developing hypotheses linking the early
biological event with the tumor response.
However, such hypotheses must be tested rig-
orously to demonstrate that a causal relation-
ship exists rather than simply a correlation of
potentially unlinked events. Similarly,
assumptions and predictions of dosimetry
models must be validated by experimentation
before being used in human risk assessments.
Public health decisions that could lead to
unrestricted use and exposure to carcinogenic
agents should not rely on untested hypotheses
(Tomatis 2002).
When high-quality human dose–response
data are available, they are used preferentially
over animal data to assess human cancer risk
(U.S. EPA 2005). However, even when ade-
quate human data are available, animal studies
are still valuable in identifying potential data
gaps in cancer risks that may not be evident in
epidemiologic studies. For example, both acry-
lamide and 1,3-butadiene induce mammary
gland tumors in rodents (Friedman et al. 1995;
Melnick and Huff 1992), whereas no associa-
tion has been reported between occupational
exposure to either of these chemicals and breast
cancer risk (IARC 1999b; Marsh et al. 1999).
Conﬂicting views on chemical carcinogenesis
may arise when animal results differ from
human results. In this case the apparent dis-
crepancy may be due simply to the lack of
female workers included in the cohort studies
of these chemicals. Thus, animal studies can
reveal inadequacies in conclusions about
potential cancer risks in the general population
that are based on occupational cohort mortal-
ity studies of healthy male workers.
Similar to animal studies, epidemiologic
studies may not detect a significant cancer
response if group size is too small or if expo-
sures are of insufﬁcient magnitude or duration.
On the basis of cancer risk estimates from ani-
mal studies on acrylamide, Dybing and Sanner
(2003) concluded that epidemiologic studies
on this chemical were not able to detect signiﬁ-
cant increases in cancer risk because of too few
participants in a dietary study (Mucci et al.
2003) and too low cumulative exposures in an
occupational cohort mortality study (Marsh
et al. 1999).
Differences in exposure scenarios between
animals and humans might affect the ability of
epidemiologic studies to detect a tumor
response identiﬁed in animal studies. For exam-
ple, if gestational or early childhood exposure is
important for tumor induction, then studies of
male workers would not be expected to pro-
duce the same response as animal studies that
include exposures during these stages of devel-
opment. Other reasons why an epidemiologic
study may not detect a true increase in risk of
certain cancers in exposed human populations
include inadequate exposure information, mis-
classifications, insufficient follow-up, and/or
inadequate study power. Because of the much
greater genetic diversity in humans compared
with speciﬁc strains of laboratory animals, the
range of expected human response may include
subgroups that are less, equally, or more sensi-
tive than the animals used in the experimental
studies. More research is needed to understand
and adequately account for factors that might
contribute to variability in human susceptibility
to chemical carcinogenesis. In the meantime, it
is prudent to assume that an induced carcino-
genic response in animals is a reliable indicator
of potential cancer risk in humans (IARC
2000; NTP 2004; U.S. EPA 2005).
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